{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:44:17Z","timestamp":1793681057498,"version":"4.5.1"},"reference-count":17,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1176\/appi.ajp.163.2.303","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T14:22:43Z","timestamp":1138717363000},"page":"303-312","source":"Crossref","is-referenced-by-count":261,"title":["Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling"],"prefix":"10.1176","volume":"163","author":[{"given":"Jon E.","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Cunningham-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Nurminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antero","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1632CHDCEGIF","doi-asserted-by":"crossref","unstructured":"Shaffer HJ, Hall MN, Vander Bilt J: Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89:1369\u20131376","DOI":"10.2105\/AJPH.89.9.1369"},{"key":"R1632CHDEFBDB","unstructured":"Potenza MN, Levinson-Miller C, Poling J, Nich C, Rounsaville BJ, Petrakis I: Gambling risk behaviors in alcohol dependent individuals with co-occurring disorders (abstract). Alcohol Clin Exp Res 2005; 28:115A"},{"key":"R1632CHDHJHAH","doi-asserted-by":"crossref","unstructured":"Hollander E, Pallanti S, Allen A, Sood E, Rossi NB: Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162:137\u2013145","DOI":"10.1176\/appi.ajp.162.1.137"},{"key":"R1632CHDCIGEJ","doi-asserted-by":"crossref","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O\u2019Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876\u2013880","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156:1758\u20131764","DOI":"10.1176\/ajp.156.11.1758"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Martin WR, Jasinski D, Mansky P: Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 1973; 23:784\u2013789","DOI":"10.1001\/archpsyc.1973.01750360022003"},{"key":"R1632CHDBFJHG","doi-asserted-by":"crossref","unstructured":"Kosten TR, Kleber HD, Morgan C: Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44:887\u2013892","DOI":"10.1016\/0024-3205(89)90589-4"},{"key":"R1632CHDBAJCH","doi-asserted-by":"crossref","unstructured":"Kim SW, Grant JE, Adson DE, Shin YC: Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49:914\u2013921","DOI":"10.1016\/S0006-3223(01)01079-4"},{"key":"R1632CHDIAJIE","doi-asserted-by":"crossref","unstructured":"Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB: A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56:719\u2013724","DOI":"10.1001\/archpsyc.56.8.719"},{"key":"R1632CHDJDEFF","doi-asserted-by":"crossref","unstructured":"Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C: A randomized double-blind fluvoxamine\/placebo crossover trial in pathological gambling. Biol Psychiatry 2000; 47:813\u2013817","DOI":"10.1016\/S0006-3223(00)00241-9"},{"key":"R1632CHDCICDH","doi-asserted-by":"crossref","unstructured":"Ikemoto S, Glazier BS, Murphy JM, McBride WJ: Role of dopa mine D1 and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci 1997; 17:8580\u20138587","DOI":"10.1523\/JNEUROSCI.17-21-08580.1997"},{"key":"R1632CHDIAEGF","doi-asserted-by":"crossref","unstructured":"Stewart J: Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacol Biochem Behav 1984; 20:917\u2013923","DOI":"10.1016\/0091-3057(84)90017-0"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Matthews RT, German DC: Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 1984; 11:617\u2013625","DOI":"10.1016\/0306-4522(84)90048-4"},{"key":"R1632CHDEHJBG","doi-asserted-by":"crossref","unstructured":"Broekkamp CL, Phillips AG: Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area. Pharmacol Biochem Behav 1979; 11:289\u2013295","DOI":"10.1016\/0091-3057(79)90137-0"},{"key":"R1632CHDBAACA","doi-asserted-by":"crossref","unstructured":"Salvato FR, Mason BJ: Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res 1994; 18:1187\u20131189","DOI":"10.1111\/j.1530-0277.1994.tb00102.x"},{"key":"R1632CHDGCAJA","doi-asserted-by":"crossref","unstructured":"Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D: Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987; 27:233\u2013239","DOI":"10.1002\/j.1552-4604.1987.tb02191.x"},{"key":"R1632CHDHDABH","doi-asserted-by":"crossref","unstructured":"Crowley TJ, Wagner JE, Zerbe G, MacDonald M: Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 1985; 142:1081\u20131084","DOI":"10.1176\/ajp.142.9.1081"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.163.2.303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T09:04:06Z","timestamp":1722157446000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.163.2.303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2,1]]}},"alternative-id":["10.1176\/appi.ajp.163.2.303"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.163.2.303","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}